

## Supplementary Online Content

Carlisle RP, Flint ND, Hopkins ZH, et al. Administrative burden and costs of prior authorizations in a dermatology department. *JAMA Dermatol*. Published online August 26, 2020.  
doi:10.1001/jamadermatol.2020.1852

**eTable.** List of all medications requiring a prior authorization in September 2016 and their prior authorization status on the last day of the month

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable.** List of all medications requiring a prior authorization in September 2016 and their prior authorization status on the last day of the month

Brand names are used when this specific branded medication was prescribed. Otherwise, when the generic medication name is listed, the medication (generic or brand) required prior authorization. Grouped alphabetically by generic medication name when available.

	<b>Approved</b>	<b>Denied</b>	<b>Pending</b>
	No. (%)	No. (%)	No. (%)
<b>Acitretin</b>	1 (0.9)	0 (0.0)	1 (0.8)
<b>Adapalene</b>	2 (1.7)	1 (1.4)	2 (1.5)
<b>Advair</b>	0 (0.0)	1 (1.4)	1 (0.8)
<b>Alcortin A</b>	0 (0.0)	1 (1.4)	1 (0.8)
<b>Benzaclin</b>	0 (0.0)	2 (2.9)	0 (0.0)
<b>Botox</b>	2 (1.7)	4 (5.8)	7 (5.4)
<b>Calcipotriene</b>	0 (0.0)	1 (1.4)	1 (0.8)
<b>Carac</b>	1 (0.9)	0 (0.0)	1 (0.8)
<b>Chantix</b>	1 (0.9)	0 (0.0)	0 (0.0)
<b>Ciclopirox</b>	0 (0.0)	2 (2.9)	0 (0.0)
<b>Clindamycin</b>	2 (1.7)	2 (2.9)	5 (3.8)
<b>Clobetasol</b>	2 (1.7)	0 (0.0)	4 (3.1)
<b>Clobex</b>	0 (0.0)	1 (1.4)	1 (0.8)
<b>Cosentyx</b>	2 (1.7)	1 (1.4)	1 (0.8)
<b>Cyclosporine</b>	3 (2.6)	0 (0.0)	2 (1.5)
<b>Dapsone</b>	1 (0.9)	0 (0.0)	0 (0.0)
<b>Aczone</b>	1 (0.0)	2 (2.9)	5 (3.8)
<b>Desonide</b>	1 (0.9)	1 (1.4)	0 (0.0)
<b>Doxycycline</b>	2 (1.7)	2 (2.9)	1 (0.8)
<b>Acticlate</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Elidel</b>	6 (5.2)	1 (1.4)	5 (3.8)
<b>Enbrel</b>	2 (1.7)	1 (1.4)	3 (2.3)
<b>Epiduo</b>	0 (0.0)	2 (2.9)	2 (1.5)
<b>Fluconazole</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Fluocinolone</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Fluocinonide</b>	0 (0.0)	1 (1.4)	0 (0.0)
<b>Humira</b>	9 (7.8)	1 (1.4)	16 (12.3)
<b>Hydrocortisone butyrate</b>	0 (0.0)	1 (1.4)	3 (2.3)
<b>Locoid</b>	1 (0.9)	1 (1.4)	1 (0.8)
<b>Hydroquinone</b>	0 (0.0)	1 (1.4)	1 (0.8)
<b>IVIg infusion</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Imiquimod</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Zyclara</b>	0 (0.0)	0 (0.0)	1 (0.8)

	<b>Approved</b>	<b>Denied</b>	<b>Pending</b>
	No. (%)	No. (%)	No. (%)
<b>Immunotherapy</b>	2 (1.7)	0 (0.0)	0 (0.0)
<b>Isotretinoin</b>	0 (0.0)	0 (0.0)	2 (1.5)
<b>Claravis</b>	6 (5.2)	1 (1.4)	2 (1.5)
<b>Zenatane</b>	6 (5.2)	1 (1.4)	5 (3.8)
<b>Myorisan</b>	2 (1.7)	1 (1.4)	1 (0.8)
<b>Itraconazole</b>	2 (1.7)	1 (1.4)	0 (0.0)
<b>Jublia</b>	1 (0.9)	1 (1.4)	2 (1.5)
<b>Methotrexate</b>	1 (0.9)	0 (0.0)	4 (3.1)
<b>Mirvaso</b>	0 (0.0)	0 (0.0)	3 (2.3)
<b>Onexton</b>	0 (0.0)	4 (5.8)	2 (1.5)
<b>Otezla</b>	1 (0.9)	2 (2.9)	5 (3.8)
<b>Prednisolone</b>	1 (0.9)	0 (0.0)	1 (0.8)
<b>QVAR inhaler</b>	0 (0.0)	1 (1.4)	1 (0.8)
<b>Remicade</b>	1 (0.9)	0 (0.0)	0 (0.0)
<b>Risedronate</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Actonel</b>	0 (0.0)	1 (1.4)	0 (0.0)
<b>Salicylic acid</b>	0 (0.0)	1 (1.4)	0 (0.0)
<b>Sitavig</b>	0 (0.0)	0 (0.0)	1 (0.8)
<b>Solodyn</b>	6 (5.2)	2 (2.9)	3 (2.3)
<b>Spectazole</b>	0 (0.0)	1 (1.4)	0 (0.0)
<b>Stelara</b>	12 (10.4)	4 (5.8)	6 (4.6)
<b>Sulfamethoxazole</b>	1 (0.9)	0 (0.0)	0 (0.0)
<b>Tacrolimus</b>	2 (1.7)	1 (1.4)	0 (0.0)
<b>Taltz</b>	2 (1.7)	0 (0.0)	1 (0.8)
<b>Tazorac</b>	2 (1.7)	2 (2.9)	3 (2.3)
<b>Tretinoin</b>	24 (20.9)	6 (8.7)	12 (9.2)
<b>Retin-A</b>	0 (0.0)	1 (1.4)	0 (0.0)
<b>Triluma</b>	0 (0.0)	2 (2.9)	0 (0.0)
<b>Urea</b>	0 (0.0)	1 (1.4)	0 (0.0)
<b>Venelex</b>	0 (0.0)	2 (2.9)	0 (0.0)
<b>Xolair</b>	3 (2.6)	1 (1.4)	4 (3.1)
<b>Ziana</b>	1 (0.9)	2 (2.9)	1 (0.8)
<b>Total</b>	<b>115 (100)</b>	<b>69 (100)</b>	<b>130 (100)</b>